Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN

Conclusions
Although it is fairly well tolerated, the HBV DNA vaccine does not decrease the risk of relapse in HBV-treated patients or the rate of virological breakthrough, and does not restore the anti-HBV immune response despite effective viral suppression by analogues.

Trial registration number
NCT00536627.

Source: Gut - December 8, 2014 Category: Gastroenterology Authors: Fontaine, H., Kahi, S., Chazallon, C., Bourgine, M., Varaut, A., Buffet, C., Godon, O., Meritet, J. F., Saidi, Y., Michel, M. L., Scott-Algara, D., Aboulker, J. P., Pol, S., for the ANRS HB02 study group Tags: Hepatology Source Type: research